Vendor Intelligence Report: Shanghai ERP peptide Biotechnology
Published 12 Nov 2026. 39-page investigative report on who is behind Shanghai ERP peptide Biotechnology: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.
Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.
Executive summary
ERP is a split-signal peptide vendor. Across 208 Finnrick lab tests, Shanghai ERP peptide Biotechnology records 162 pass / 41 fail, an overall pass rate of 78%. The strongest lane is Retatrutide, with GHK-Cu also testing well and Tirzepatide comparatively usable; the weak tail is materially different, with NAD+, TB-500 and HGH among the products that should not be bought on vendor reputation alone. Ratings also compress under stricter methodology, so the full product view matters.
The dominant non-purity finding is Health Canada RA-82930: a public advisory naming ERP, reporting bacteria in injectable peptides and describing the seizure of more than 11,400 vials from ERP and two Canadian retailers. That finding is separate from the usual unapproved-drug issue in this market; it goes to sterility and channel control. The overlap includes products with comparatively strong Finnrick purity/fill rows, so purity and sterility cannot be collapsed into one score.
ERP’s operating map is unusually messy. The official site was revived, the transaction flow runs through persona storefronts, and ERP itself has warned against two close lookalike domains, including a plural-domain clone using familiar branding. Public sources reviewed did not verify a Chinese legal entity, UBO, registered address, named quality lead or manufacturer for the active network; the COA record contains historical reports, broken links and documentation-control artifacts rather than a clean lot-to-vial chain.
Inside the full report:
- Per-product pass/fail rates, rating trajectories and methodology-divergence charts for all 16 tested products
- Health Canada RA-82930 analysis, seizure photographs and Canadian retailer status checks
- Official-channel map covering erppeptide.com, erppeptide.shop, persona storefronts and disavowed lookalikes
- Domain, DNS, Zoho mail, registrar and infrastructure forensics across the ERP ecosystem
- COA-library review, broken certificate checks and batch-traceability analysis
- Ownership, quality-accountability and open-lead assessment for the unresolved Chinese entity trail
Risk assessment
- Bacterial-contamination and Canadian channel risk — high: Health Canada RA-82930 reported bacteria in ERP injectables, named hCG, MOTS-C, NAD+, Retatrutide, Tesamorelin and Tirzepatide as examples, and stated that more than 11,400 vials were seized.
- Product-specific quality risk: NAD+, TB-500, HGH, 5-Amino-1MQ, Glutathione, Cagrilintide — high: Finnrick ratings are weak for NAD+ 27.97%, TB-500 39.84%, HGH 40.26%, 5-Amino-1MQ 47.11%, Glutathione 49.89% and Cagrilintide 53.31%; avoid or independently test these products.
- Product-specific verification risk: BPC-157, hCG, Ipamorelin, Melanotan II, Tesamorelin — medium: These products sit in the caution band, including BPC-157 60.07%, hCG 59.77%, Ipamorelin 66.21%, Melanotan II 65.68% and Tesamorelin 69.67%; verify current lot before buying.
- Ownership and quality-accountability opacity — high: No verified legal entity, UBO, registered address, officer, manufacturer or named quality lead was found for the active ERP network, and the gap is material after documented control events.
- Copycat and brand-confusion risk — high: ERP disavowed erpbiotechnology.com and erppeptides.shop; the plural-domain clone remained live using ERP-like copy and Emmy branding, while ERP lacks robust anti-counterfeit controls.
- COA and documentation-control risk — medium: ERP shows historical COA libraries, but public pages also include broken certificate links, repeated older reports, broken Veragene facility imagery and template artifacts from Prime Peptides.
- Affiliate-promotion risk — medium: ERP runs public affiliate recruitment with inconsistent commission terms and no buyer-facing affiliate-disclosure control found, although no specific undisclosed third-party promoter was verified.